|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
IL99552A0
(en)
|
1990-09-28 |
1992-08-18 |
Ixsys Inc |
Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
|
|
EP1099445A3
(en)
|
1993-06-10 |
2001-09-05 |
Allergan, Inc. |
Treatment of neuromuscular disorders and conditions with different botulinum serotype
|
|
US5437291A
(en)
|
1993-08-26 |
1995-08-01 |
Univ Johns Hopkins |
Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
|
|
US6974578B1
(en)
|
1993-12-28 |
2005-12-13 |
Allergan, Inc. |
Method for treating secretions and glands using botulinum toxin
|
|
US20040126396A1
(en)
|
1993-12-28 |
2004-07-01 |
Allergan, Inc. |
Botulinum toxin treatment for strabismus
|
|
US5670484A
(en)
|
1994-05-09 |
1997-09-23 |
Binder; William J. |
Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
|
|
US5714469A
(en)
|
1994-09-01 |
1998-02-03 |
Smithkline Beecham Corporation |
Method of treating sepsis
|
|
US6063768A
(en)
|
1997-09-04 |
2000-05-16 |
First; Eric R. |
Application of botulinum toxin to the management of neurogenic inflammatory disorders
|
|
GB9818548D0
(en)
|
1998-08-25 |
1998-10-21 |
Microbiological Res Authority |
Treatment of mucas hypersecretion
|
|
US6767544B2
(en)
|
2002-04-01 |
2004-07-27 |
Allergan, Inc. |
Methods for treating cardiovascular diseases with botulinum toxin
|
|
US6358917B1
(en)
|
1999-08-24 |
2002-03-19 |
Jean D. A. Carruthers |
Cosmetic use of botulinum toxin for treatment of downturned mouth
|
|
HK1046020B
(en)
|
1999-08-25 |
2007-05-11 |
Allergan, Inc. |
Activatable recombinant neurotoxins
|
|
GB9922554D0
(en)
|
1999-09-23 |
1999-11-24 |
Microbiological Res Authority |
Inhibition of secretion from non-neuronal cells
|
|
US6113915A
(en)
|
1999-10-12 |
2000-09-05 |
Allergan Sales, Inc. |
Methods for treating pain
|
|
US6265379B1
(en)
|
1999-10-13 |
2001-07-24 |
Allergan Sales, Inc. |
Method for treating otic disorders
|
|
US7838008B2
(en)
|
1999-12-07 |
2010-11-23 |
Allergan, Inc. |
Methods for treating diverse cancers
|
|
US6139845A
(en)
|
1999-12-07 |
2000-10-31 |
Allergan Sales, Inc. |
Method for treating cancer with a neurotoxin
|
|
US6337075B1
(en)
|
2000-01-11 |
2002-01-08 |
Allergan Sales, Inc. |
Methods for treating diabetes
|
|
US6143306A
(en)
|
2000-01-11 |
2000-11-07 |
Allergan Sales, Inc. |
Methods for treating pancreatic disorders
|
|
US6261572B1
(en)
|
2000-01-11 |
2001-07-17 |
Allergan Sales, Inc. |
Method for treating a pancreatic disorder with a neurotoxin
|
|
US6641820B1
(en)
|
2000-01-19 |
2003-11-04 |
Allergan, Inc. |
Clostridial toxin derivatives and methods to treat pain
|
|
US6524580B1
(en)
|
2000-02-15 |
2003-02-25 |
Allergan Sales, Inc. |
Method for treating thyroid disorders
|
|
US6464986B1
(en)
|
2000-04-14 |
2002-10-15 |
Allegan Sales, Inc. |
Method for treating pain by peripheral administration of a neurotoxin
|
|
US6299893B1
(en)
|
2000-04-17 |
2001-10-09 |
Marvin Schwartz |
Method to reduce hair loss and stimulate hair regrowth
|
|
US6565870B1
(en)
|
2000-04-28 |
2003-05-20 |
Allergan, Inc. |
Methods for treating bone tumors
|
|
US6306403B1
(en)
|
2000-06-14 |
2001-10-23 |
Allergan Sales, Inc. |
Method for treating parkinson's disease with a botulinum toxin
|
|
US6903187B1
(en)
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US6423319B1
(en)
|
2000-10-04 |
2002-07-23 |
Allergan Sales, Inc. |
Methods for treating muscle injuries
|
|
US6827931B1
(en)
|
2000-10-20 |
2004-12-07 |
Allergan, Inc. |
Method for treating endocrine disorders
|
|
US7273722B2
(en)
|
2000-11-29 |
2007-09-25 |
Allergan, Inc. |
Neurotoxins with enhanced target specificity
|
|
US6623742B2
(en)
|
2001-09-17 |
2003-09-23 |
Allergan, Inc. |
Methods for treating fibromyalgia
|
|
US7255866B2
(en)
|
2001-09-17 |
2007-08-14 |
Allergan, Inc. |
Botulinum toxin therapy for fibromyalgia
|
|
US6921538B2
(en)
|
2002-05-10 |
2005-07-26 |
Allergan, Inc. |
Therapeutic treatments for neuropsychiatric disorders
|
|
JP2006513994A
(ja)
|
2002-10-15 |
2006-04-27 |
アラーガン、インコーポレイテッド |
ボツリヌス毒素歯科治療および歯科措置
|
|
US7238357B2
(en)
|
2002-11-05 |
2007-07-03 |
Allergan, Inc. |
Methods for treating ulcers and gastroesophageal reflux disease
|
|
US8071550B2
(en)
|
2003-03-03 |
2011-12-06 |
Allergan, Inc. |
Methods for treating uterine disorders
|
|
US6838434B2
(en)
|
2003-05-02 |
2005-01-04 |
Allergan, Inc. |
Methods for treating sinus headache
|
|
US7220422B2
(en)
|
2003-05-20 |
2007-05-22 |
Allergan, Inc. |
Methods and compositions for treating eye disorders
|
|
US20040253274A1
(en)
|
2003-06-11 |
2004-12-16 |
Allergan, Inc. |
Use of a clostridial toxin to reduce appetite
|
|
ES2369558T3
(es)
|
2005-09-19 |
2011-12-01 |
Allergan, Inc. |
Toxinas clostridiales y toxinas clostridiales activables.
|
|
EP1834962A1
(de)
|
2006-03-15 |
2007-09-19 |
Biotecon Therapeutics GmbH |
PEGyliertes mutiertes Clostridium botulinum Toxin
|
|
WO2009015840A2
(en)
*
|
2007-07-27 |
2009-02-05 |
Merz Pharma Gmbh & Co. Kgaa |
Polypeptide for targeting of neural cells
|
|
GB0903006D0
(en)
|
2009-02-23 |
2009-04-08 |
Syntaxin Ltd |
Modified non-cytotoxic proteases
|
|
CA2758274C
(en)
|
2009-04-14 |
2018-04-10 |
Mcw Research Foundation, Inc. |
Engineered botulinum neurotoxin
|
|
US8853360B2
(en)
|
2010-06-23 |
2014-10-07 |
Wisconsin Alumni Research Foundation |
Engineered botulinum neurotoxin C1 with selective substrate specificity
|
|
WO2014079495A1
(en)
|
2012-11-21 |
2014-05-30 |
Syntaxin Limited |
Methods for the manufacture of proteolytically processed polypeptides
|
|
GB201312317D0
(en)
*
|
2013-07-09 |
2013-08-21 |
Syntaxin Ltd |
Cationic neurotoxins
|
|
EP3481852B1
(en)
*
|
2016-07-08 |
2022-12-07 |
Children's Medical Center Corporation |
A novel botulinum neurotoxin and its derivatives
|
|
EP3335719A1
(en)
*
|
2016-12-14 |
2018-06-20 |
Merz Pharma GmbH & Co. KGaA |
Novel recombinant botulinum neurotoxins with a stabilized light chain
|
|
GB201815817D0
(en)
|
2018-09-28 |
2018-11-14 |
Ispen Biopharm Ltd |
Clostridial neurotoxins comprising and exogenous activation loop
|